 This study will be conducted by all participating medical centers to the Lymphoma Disease Committee 14 centers in total. Since the rituximab-CHOP chemotherapy is the standard first-line treatment for patients with diffuse large B-cell NHL and follicular cell NHL, no center interaction on treatment is expected in this study. 